CAS No. |
1638750-96-5 |
中文名称 |
二铵(2R,5R,7R,8R,10R,12aR,14R,15R,15aS,16R)-7,14-双(6-氨基-9H-嘌呤-9-基)-15,16-二羟基-2,10-二巯基-八氢-12H-5,8-亚甲基-呋喃并[3,2-l][1,3,6,9,11]五氧杂[2,10]二磷杂环十四碳烯-2,10-二氧化物盐 |
英文名称 |
(2R,5R,7R,8R,10R,12aR,14R,15R,15aS,16R)-7,14-Bis(6-amino-9H-purin-9-yl)-15,16-dihydroxy-2,10-dimercaptooctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11]pentaoxa[2,10]diphosphacyclotetradecine 2,10-dioxide diammonium salt |
别名 |
ML RR-S2 CDA (ammonium salt);Adenosine, [P(R)]-5'-O-[(R)-hydroxymercaptophosphinyl]-P-thioadenylyl-(2'→5')-, cyclic nucleotide, ammonium salt (1:2);ADU-S100 ammonium salt;STING-INDUCER-1 AMMONIUM SALT;MIW815 ammonium salt;ML RR-S2 CDA ammonium salt(ADU-S100);inhibit,ADU S100 ammonium salt,TMEM173,STING,MIW815,Inhibitor,MIW-815,Stimulator of Interferon Genes,MITA,MPYS,ERIS,ADU-S100,ML RR-S2 CDA,MIW 815,ADUS100 ammonium salt;ADU-S100 ammonium salt, 10 mM in DMSO |
标准英文名 |
(2R,5R,7R,8R,10R,12aR,14R,15R,15aS,16R)-7,14-bis(6-amino-9H-purin-9-yl)-15,16-dihydroxy-2,10-dimercaptooctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11]pentaoxa[2,10]diphosphacyclotetradecine 2,10-dioxide, diammonia salt |
分子式 |
C20H30N12O10P2S2 |
分子量 |
724.62
|
精确分子量 |
724.11
|
SMILES |
N.N.NC1=C2N=CN([C@@H]3O[C@@H]4CO[P@@](=O)(S)O[C@@H]5[C@H](O)[C@@H](CO[P@@](=O)(S)O[C@H]4[C@H]3O)O[C@H]5N3C=NC4=C(N)N=CN=C43)C2=NC=N1 |
标准SMILES |
N.N.NC1N=CN=C2C=1N=CN2[C@@H]1O[C@@H]2CO[P@@](=O)(S)O[C@H]3[C@@H](O[C@H](CO[P@@](=O)(S)O[C@H]2[C@H]1O)[C@H]3O)N1C=NC2C1=NC=NC=2N |
用途 |
ADU-S100 ammonium salt (MIW815 ammonium salt) is a potent activator of STING (Stimulator of Interferon Genes), exhibiting strong antitumor and immunostimulatory activities; it enhances type I IFN production in THP-1 human monocytes compared to CDA; potently activates all five human STING alleles, including the refractory hSTING REF and hSTING Q variants; induces the highest expression of IFN-β and pro-inflammatory cytokines TNF-α, IL-6, and MCP-1 on a molar equivalent basis compared to endogenous ML-cGAMP and the TLR3 agonist poly(I:C); triggers STING aggregation and phosphorylation of TBK1 and IRF3 in mouse bone marrow-derived macrophages (BMMs); elicits significantly higher levels of IFN-α than ML-cGAMP; demonstrates superior in vivo antitumor efficacy compared to endogenous ML-cGAMP; in B16 tumor-bearing mice, it achieves optimal antitumor control at a specific dose that also maximizes tumor antigen-specific CD8+ T cell responses and improves long-term survival to 50%. |
InChIKey |
VZYXAGGQHVUTHM-ITQXCAEYSA-N |